Compare Cytokinetics Inc (CYTK) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Cytokinetics Inc trades at $81.69 (market cap $11.12B), while Vanguard Information Technology Index Fund ETF trades at $116.34. The key difference: Cytokinetics Inc is trading nearer its 52-week high, Vanguard Information Technology Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | VGT | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | — |
52-Week High | $87.26 | $125.77 |
52-Week Low | $33.23 | $83.59 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
VGT trades at $115.58, down 2.12% on the day amid a neutral technical signal. The ETF's moving averages show bearish momentum, while oscillators are neutral. Recent news highlights strong 2026 performance against the S&P 500 and ongoing investor interest in tech ETFs, though fee comparisons with competitors like FTEC are noted. A 1:8 stock split occurred in April 2026, with a small dividend scheduled for June 2026.
Outlook remains tied to tech sector strength and AI-driven earnings, but risks include valuation sensitivity and sector volatility. The ETF's low expense ratio and broad diversification offer a cost-effective tech exposure, yet overlap costs and hyperscaler capex guidance in H2 2026 warrant monitoring for potential pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
